Institutional investors purchased a net $4.1 million shares of HALO during the quarter ended March 2016. This may signal that the smart money is gaining interest in this company as the 65.69% of shares outstanding that institutional investors hold is actually below the Biotechnology industry average.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
FIRST EAGLE INVESTMENT MANAGEMEN... Bought 2.4 Million shares of Halozyme Therapeutics Inc
SNYDER CAPITAL MANAGEMENT LP Bought 1.7 Million shares of Halozyme Therapeutics Inc